Sunday

EACPT 2009 - Edinburgh International Conference Centre Sunday 12th July Room A DRUG DISCOVERY, DEVELOPMENT and SAFETY From laboratory to patient Drug Interactions Matthias Schwab (DE) - The clinical relevance of drug-drug Session 1 Room B BRITISH PHARMACOLOGICAL SOCIETY Clinical Pharmacology Symposium Clinical Pharmacology: Working with Patients Colin Baigent (UK) - Understanding the uses and limitations of RCTs 09.30 - 09.45 and drug-herb interactions 09.45 - 10.00 10.00 - 10.15 drug-drug interactions 10.15 - 10.30 Rashmi Shah (UK) - The evolution of regulatory guidance on Ragnar Lofstedt (UK) - Risk communication and health: relevance to therapeutics Geoff Tucker (UK) - The prediction of metabolic drug-drug John Urquhart (CH) - Concordance, compliance and adherence 10.30 - 10.45 interactions from in vitro data 10.45 - 11.00 11.00 - 11.30 Coffee Break Drug Interactions Session 2 Coffee Break Clinical Pharmacology: Working with Patients 11.30 - 11.45 Roeline Jochemsen (FR) - Drug-drug interactions as an issue Munir Pirmohamed (UK) - Anticipating adverse drug reactions 11.45 - 12.00 in drug development 12.00 - 12.15 Martin Fromm (DE) - How important are transporters in drug- David Back (UK) - Anticipating adverse drug interactions 12.15 - 12.30 12.30 - 12.45 12.45 - 13.00 13.00 - 14.00 Session 3 drug interactions? Theodor Guentert (CH) - Harnessing beneficial effects from drug-drug interactions: Fact or fiction. Jeff Aronson (UK) - What information do we need to prescribe rationally? Lunch Specialised Methods in Drug Discovery Lunch Clinical Pharmacology: Working with Patients 14.00 - 14.15 Stephen Rees (UK) - High Throughput Screening Approaches Mark Sculpher (UK) - How can we measure cost14.15 - 14.30 to Support Drug Discovery effectiveness? 14.30 - 14.45 John Haselden (UK) - Metabolic Profiling in Pharma R&D Martin Duerden (UK) - Formularies: why do we need them and how do you make one? John Haselden (UK) - Metabolic Profiling in Pharma R&D 14.45 - 15.00 15.00 - 15.15 15.15 - 15.30 15.30 - 16.00 Session 4 Philippe Beaune (FR) - Pharmacogenomics: from drug development to clinical use Martin Duerden (UK) - Formularies: why do we need them and how do you make one? Simon Maxwell (UK) - Ethical issues in clinical pharmacology Coffee Break Specialised Methods in Drug Discovery Coffee Break Debate The pharmaceutical industry should have a greater role in providing patients with drug information For David Gillen (UK) Against - Des Spence (UK) 16.00 - 16.15 Gert Auer (SE) - Improved methodologies of proteomics 16.15 - 16.30 16.30 - 16.45 Colin Garner (UK) - Microdosing in drug screening 16.45 - 17.00 17.00 - 17.15 Oliver von Richter (DE) - Predicting drug transport 17.15 17.30 17.45 18.00 18.15 17.30 17.45 18.00 18.30 18.30 OPENING CEREMONY Opening Plenary Lecture - Sir Colin Dollery (UK) - Clinical Pharmacology - past, present and future Room C SPECIAL SYMPOSIA EICC FOYER Registration Coffee Break Debate European clinical trialists are grossly over-regulated and under-supported For - John Cockcroft (UK) Against - Kent Woods (UK) Lunch Clinical Pharmacology in Eastern Europe Emil Gatchev (BG) - Clinical trials in Eastern Europe: is there still a chance for us? Igor Francetic (HR) - Rational prescribing and pharmacovigilance in Eastern Europe Sandor Kerpel-Fronius (HU) - Education in Eastern Europe: Quo vadis? Registration Desks Open All Day Registration Desks Open All Day Prof Dr Violeta Stanimirovic (SE) - Regulatory environment in the non-EU European countries Discussion with contributions from Nedzad Mulabegovic, Vangelis Manolopoulos, Viktorija Dragojevic-Simic and Josef Glasa Coffee Break Clinical Pharmacology in Eastern Europe T. Madjarevic (HR) - Normal 0 21 bisphosphonates usage in Croatia: The effects of new pricing regulation M. Aščerić (BA) - Issuance of antibiotics without prescription M. Blöndal (EE) - Use of statins after myocardial infarction in Estonia N. Djordjevic (SE) - Correlation of CYP2A6 enzyme activity with genotype and cigarette smoking in Serbs C.Dafni (GR) - Relationship between a polymorphism of the e-NOS gene and myocardial infarction in a subgroup of Greek MI patients ogy - past, present and future EACPT 2009 - Edinburgh International Conference Centre Monday 13th July Theme A DRUG DISCOVERY, DEVELOPMENT and SAFETY From laboratory to patient Drug Discovery Theme B ORGAN-BASED THERAPEUTICS Targeting common diseases Hypertension (ARTERY) John Cockcroft (UK) - Vascular stiffness - a key factor in hypertension Stephane Laurent (FR) - What drugs should we be using to treat hypertension Session 1 08.30-08.45 Julio Benitez (ES) - Drug discovery in the ‘post-genomic era’ 08.45-09.00 09.00-09.15 Adam Cohen (NL) - Early drug studies in man - what have we 09.15-09.30 learned from TGN1412 09.30-09.45 R. Roubin (AU) - Structure based drug design and type 2 diabetes - a success story 09.45-10.00 S. Aschauer (AT) - Association of a genetic variation on chromosome 9p21.3 with reduced arterial vasodilator function in healthy volunteers J. Hay (NL) - Pharmacodynamic testing with the NeuroCart in early Y. Azekoshi (JP)- Angiotensin II attenuates vasodilation by ANP in phase drug development: A meta-analysis of 20 years of CNS research humans: Roles of cGMP bioavailability and angiotensin II type 1 receptor 10.00-10.30 Coffee Break Session 2 Clinical Trials 10.30-10.45 Gordon Murray (UK) - New approaches to clinical trial design 10.45-11.00 and analysis 11.00-11.15 I.S. Mackenzie (UK) - The ‘Get Randomised’ campaign: Promoting understanding of randomised clinical trials through the media Coffee Break EPHAR Lecture Professor Juan Tamargo (ES) - Emerging drugs for the treatment of acute heart failure syndromes 11.15-11.30 M. Boettcher (DE) - Incidence of adverse events in early phase I - a meta analysis of bioavailability/interaction studies conducted at the Bayer in-house ward (2000–2005) 11.30-11.45 11.45-12.00 12.00-12.15 12.15-13.00 13.00-13.15 13.15-13.30 13.30-13.45 13.45-14.00 Plenary Lecture - Patrick Vallance (UK) - The interface between clinical pharmacology in academia and t Lunch and Poster Viewing Guided Posters: Cardiovascular disease, Drug discovery, Drug regulation, Neurology, Psychiatry, Pain, Clinical trials, Analytical pharm Plenary Poster Session and Prize Award Session 3 Drug Regulation Lipids Chris Packard (UK) - Optimal cholesterol-lowering therapy what LDL targets should we achieve? Paul Durrington (UK) - Raising HDL and other new approaches A. Bucsics (US) - Impact of reimbursement changes on statin use among patients with diabetes in Austria M. Okorie (UK) - Oral inorganic nitrate protects against endothelial ischaemia-reperfusion injury in humans 14.00-14.15 Hans-Georg Eichler (AT) - EMEA: Regulating medicines in 14.15-14.30 Europe 14.30-14.45 Alasdair Breckenridge (UK) - Risk management in drug 14.45-15.00 regulation 15.00-15.15 A. Chain (NL) - Not-in-trial simulation: Predicting cardiovascular risk 15.15-15.30 from clinical trial data M. Tobaiqy (UK) - A pilot study to evaluate a community pharmacy based monitoring system to identify adverse drug reactions (ADRs) associated with paediatric medicines use Coffee Break 15.30-16.00 Late Breaking Abstracts Session 4 Coffee Break Diabetes Baptist Gallwitz (DE) - Novel therapeutic strategies for type 2 diabetes 16.00-16.15 T.M. Macdonald (UK) - RAND appropriateness study with development of recommendations for NSAID treatment 16.15-16.30 E.H.Baker (UK) - Use of retrospective data to identify a suitable 16.30-16.45 16.45-17.00 Satellite endpoint for a randomised controlled trial in COPD patients with acute exacerbations V.G. Manolopoulos (GR) - Association of CYP2C9 and Kir6.2 gene polymorphisms with hypoglycaemia in type 2 diabetic patients treated with sulphonylurea B.B. Heinisch (AT) - Alpha-lipoic acid treatment improves vascular endothelial function in patients with type 2 diabetes British Pharmacological Society Hypertension Symposium Chair: Prof Gordon McInnes Morris Brown (UK) - Prediction of antihypertensive response - phenotype? Mark Caulfield (UK) - Prediction of antihypertensive response - genotype? Ian Wilkinson (UK) - What response - brachial artery or aorta? Matthew Walters (UK) - The lower the better? - recent experience in stroke 17.00-17.25 17.25-17.50 17.50-18.15 18.15-18.40 19.00-22.00 Welcome Reception, Edinburgh Castle Theme C THERAPEUTICS in SPECIAL GROUPS Neurology/Cancer/Old/Young Neurodegeneration Ezio Giacobini (CH) - Drugs to improve cognitive function Laszlo Vecsei (HU) - Parkinson's Disease: will therapy move beyond dopamine receptor agonists? M. Bauer (AT) - A pilot study to assess the efficacy of tariquidar to inhibit cerebral P-glycoprotein in humans with (R)–[11C]verapamil and PET G.P. Zara (IT) - Pharmacokinetics and brain biodistribution of apomorphine incorporated in solid lipid nanoparticles Coffee Break Psychiatric Disease Nicol Ferrier (UK) - Optimal management of depression G.E. Jacobs (NL) - 7-tesla functional proton magnetic resonance spectroscopy of serotonergic hypothalamic activation in healthy volunteers OE Della Pasqua (UK) - The missing link between clinical endpoint and pharmacological receptor systems in depression macology in academia and the industry linical trials, Analytical pharmacology, Metabolic disease, Drug d Pain Management Soren Sindrup (DK) - Recent advances in the management of neuropathic pain Maria Adele Giamberardino (IT)- Controlling pain in the postoperative setting S.T. Zwisler (DK) - Impact of CYP2D6 genotype on postoperative intravenous oxycodone analgesia K. Burggraaf (NL) - Development and evaluation of a continuous intravenous infusion of acetaminophen in cardiac surgery patients Coffee Break Epilepsy Emilio Perucca (IT) - New drug developments in epilepsy J.-D. Huang (TW) - Effects of P-glycoprotein polymorphism on phenytoin absorption N Moore (FR) - Levetiracetam one year retention rate in real-life practice in France, final results of the EULEV study e EACPT 2009 - Edinburgh International Conference Centre Tuesday 14th July Theme A DRUG DISCOVERY, DEVELOPMENT and SAFETY From laboratory to patient Health Technology Assessment Theme B ORGAN-BASED THERAPEUTICS Targeting common diseases Heart Disease David Newby (UK) - Optimising treatment for acute coronary syndromes Aldo Maggioni (It) - Heart failure: do we need any more drugs? Z. Qureshi (UK) - Gender differences in baseline platelet reactivity and response to clopidogrel, but not aspirin, may contribute to the increased risk in young women with cardiovascular disease M. Brunner (AT) - Blockade of the renin-angiotensin-system by the angiotensin-converting enzyme inhibitor ramipril alters gene expression in skeletal muscle in healthy subjects Session 1 08.30-08.45 David Webb (UK) - Early assessment of cost-effectiveness 08.45-09.00 09.00-09.15 Michael Rawlins (UK) - NICE: has it produced 'clinical 09.15-09.30 excellence'? 09.30-09.45 S. Hems (UK) - An investigation of how the Scottish Medicines Consortium (SMC) has shaped medicines use across NHSScotland 09.45-10.00 10.00-10.30 Session 2 A.Brown (UK) - How much good do new medicines do? Coffee Break Pharmacovigilance (ISOP) Coffee Break Heart Disease Greg Lip (UK) - Atrial fibrillation - what is optimal treatment now? 10.30-10.45 Petra Thuermann (D) - Surveillance for ADRs - have we moved on from spontaneous reports? 10.45-11.00 11.00-11.15 11.15-11.30 11.30-11.45 11.45-12.00 12.00-12.15 12.15-13.00 U. Bergman (SE) - Pharmacovigilance and patient safety - a plea for regional pharmacovigilance centres A. Helldén (SE) - The incidence of aciclovir-induced neuropsychiatric symptoms in Stockholm E. Poluzzi (IT) - Antimicrobial-induced torsades de pointes: Towards risk stratification by data-mining of the FDA Adverse Event Reporting System V. Kapil (UK) - Blood pressure lowering effects of oral inorganic nitrate via bioconversion to nitrite Plenary Lecture - Garret Fitzgerald (US) - Translational medicine: past successes and future challenges Lunch and Poster Viewing 13.00-13.15 13.15-13.30 13.30-13.45 13.45-14.00 Session 3 EACPT GENERAL ASSEMBLY Guided Posters: Adverse drug reactions/drug toxicity, Pharmacoepidemiology, Pharmacov Pharmacokinetics, Oncology, Critical care medicine, Infection and immunity, Biomarke Plenary Poster Session and Prize Award Stroke Peter Sandercock (UK) - What have we learned from the stroke trials? Domenico Inzitari (I) - Future strategies to improve outcome in acute stroke J.Dawson (UK) - Effect of allopurinol upon cerebrovascular reactivity following subcortical stroke R. Flynn (UK) - Systematic review of observational research studying longterm use of antithrombotic medicines following haemorrhagic stroke Pharmacoepidemiology (ISPE) 14.00-14.15 Nicholas Moore (Fr) - The role of pharmacoepidemiology in 14.15-14.30 14.30-14.45 Tom MacDonald (UK) - Record linkage studies in research 14.45-15.00 15.00-15.15 15.15-15.30 15.30-16.00 Session 4 M.Dall (DK) - Use of selective serotonin reuptake inhibitors and upper GI bleeding L. Wei (UK) - A population-based time-series analysis of spironolactone use and renal toxicity pharmacovigilance Coffee Break Medication Errors and Adverse Events Coffee Break Anticoagulants Martin Wehling (D) - Future of anticoagulant therapy P.I. Elofuke (UK) - Retrospective audit of pre-admission warfarin use in acute stroke patients with pre-existing atrial fibrillation B.Godman (IT) - Impact of reforms to enhance the quality and efficiency of statin prescribing across 20 European countries 16.00-16.15 Robin Ferner (UK) - Medication errors - worse than a crime 16.15-16.30 16.30-16.45 E.C.Davies (UK) - Emergency readmissions to hospital due to adverse drug reactions (ADRs): A retrospective study 16.45-17.00 Satellite S. Mueller (DE) - Adverse drug reactions (ADR) leading to hospital admission with a fatal outcome Clinical Pharmacological Services to Health Care - The Scandinavian Approach Chair: Prof Folke Sjoqvist and Prof Kim Brosen Ylva Böttiger (SE) - Drug information services today – from databases to patients and back to data bases Johan Ahlner (SE) - Therapeutic drug monitoring and drug toxicology Erik Eliasson (SE) - Pharmacogenetic services Morten Andersen (DK) - Pharmacoepidemiological services 17.00-17.25 17.25-17.50 17.50-18.15 18.15-18.40 20.00-24.00 Conference Dinner, Dynamic Earth Theme C THERAPEUTICS in SPECIAL GROUPS Neurology/Cancer/Old/Young Cancer Herbie Newell (UK) - Novel targets for anticancer agents Duncan Jodrell (UK) - New designs in cancer trials Coffee Break Pharmacokinetics/Biomarkers C. Wagner - Combined accelerator mass spectrometry and positron emission tomography microdosing to assess plasma and brain tissue pharmacokinetics of verapamil in humans L. Noehr-Jensen - Impact of CYP2C19 phenotypes on escitalopram pharmacokinetics and evaluation of pupillometry as a biomarker of serotonergic effect D.A. Hughes (UK) - A systematic review and empirical analysis of the relation between dose and duration of drug action T. Füreder (AT) - Targeting sphingosine kinase 1 with LNA oligonucleotides in gastric cancer ccesses and future challenges Pharmacoepidemiology, Pharmacovigilance, Pharmacoeconomics, ne, Infection and immunity, Biomarkers, Genomics/proteomics Critical Care Medicine Else Tonnesen (Den) - Strategies to treat sepsis - old and new Ulrich Kunzendorf (D) - New pharmacologic therapies for acute renal failure S. Eslami (NL) - Implementing glucose regulation guidelines in intensive care – a multicenter trial using statistical process control L. Schmetterer (AT) - Reactivity of retinal blood flow to 100% oxygen breathing after LPS administration in healthy subjects Coffee Break Antimicrobials (ISPOR) Peter Davey (UK) - Overcoming the challenge of resistance P. Papaioannidou (GR) - Quality of antibiotic prescribing for prophylaxis in general surgery: Results from 15 general surgery departments in 10 countries R. Sauermann (AT) - Abscess penetration of cefpirome in humans EACPT Council Meeting EACPT 2009 - Edinburgh International Conference Centre Wednesday 15th July Theme A DRUG DISCOVERY, DEVELOPMENT and SAFETY From laboratory to patient Toxicology (EAPCCT) Theme B ORGAN-BASED THERAPEUTICS Targeting common diseases Gastrointestinal Disease Chris Hawkey (UK) - Drugs that cause and heal peptic ulcer disease Jack Satsangi (UK) - Novel approaches to managing inflammatory bowel disease S.E. Gulmez (DK) - Do statins protect against upper gastrointestinal bleeding? B.Godman (IT) - Trends in consumption and expenditure of proton pump inhibitors (PPIs) in 20 European countries Session 1 08.30-08.45 Kevin Park (UK) - Mechanisms of drug-induced hepatotoxicity 08.45-09.00 09.00-09.15 Nick Bateman (UK) - Common poisonings - is treatment 09.15-09.30 improving? 09.30-09.45 M.P.J. Nicolai (NL) - Cyclophilin A is a mediator of paracetamol-induced liver injury 09.45-10.00 M. Eddleston (UK) - A Gottingen minipig model of dimethoate organophosphorus pesticide poisoning 10.00-10.30 Coffee Break Session 2 Drugs of Abuse 10.30-10.45 Michael Gossop (UK) - New pharmacological approaches to 10.45-11.00 tackling drug addiction 11.00-11.15 HD Kleinloog (NL) - Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects Coffee Break Rheumatology Iain McInnes (UK) - Biological therapies for rheumatic disease K.Brune (DE) - Can drug removals involving cyclooxygenase-2 inhibitors be avoided? Results from volunteer studies 11.15-11.30 11.30-11.45 11.45-12.00 12.00-12.15 12.15-13.00 13.00-13.15 13.15-13.30 N. Kostic (RS) - Patients drug abusing in the primary health institution P. McGettigan (UK) - Polymorphisms in two regions of the cyclo-oxygenase2 gene associated with variation in risk of coronary thrombosis with cyclooxygenase-2 inhibitors Plenary Lecture - Alastair Wood (US) - Is it time to shake up the drug approval process? Lunch and Poster Viewing Guided Posters: Clinical toxicology/drug poisoning, Gastroenterology and hepatology, Bone and joint disease, Lung disease, Nephrology, Paediatric c clinical pharmacology, Other special populations, Pharmacotherapeutics, Rational prescribing 13.30-13.45 13.45-14.00 Session 3 Educating Prescribers Plenary Poster Session and Prize Award Pulmonary Disease Jorgen Vestbo (DK) - Drug treatment of COPD: present and future 14.00-14.15 Simon Maxwell (UK) - What defines 'competent prescribing' in a 14.15-14.30 newly qualified doctor? Peter Barnes (UK) - Cytokines/chemokines as drug targets in 14.30-14.45 Theo de Vries (NL) - How do we train competent prescribers? asthma 14.45-15.00 15.00-15.15 S Ross (UK) - Do educational interventions improve prescribing by medical N. Moore (FR) - Antibiotic effectiveness to prevent new chronic obstructive students and junior doctors? A systematic review pulmonary disease (COPD) exacerbations in current medical practice 15.15-15.30 A.B.D. van Doorn (NL) - A national multicentre e-learning programme to promote cooperation and to support rational prescribing by future physicians and pharmacists P.A. Reece (AU) - Zanamivir PK/PD: Implications for the treatment of avian influenza (H5N1) infections in humans 15.30-16.00 Coffee Break Session 4 Educating Prescribers 16.00-16.15 16.15-16.30 16.30-16.45 16.45-17.00 C. Burgess (NZ) - Perceptions of prescribing ability and clinical pharmacology education amongst PGY1 and PGY2 doctors J. Tichelaar (NL) - A ‘SMART’ way to learn how to determine a therapeutic goal P. McGettigan (UK) - Training medical students to prescribe: HYMS’ evolving teaching model Coffee Break Late Breaking Abstracts CLOSING CEREMONY Theme C THERAPEUTICS in SPECIAL GROUPS Neurology/Cancer/Old/Young Paediatric Pharmacology Maurizio Bonati (IT) - Current issues in paediatric prescribing M.J. Ahsman (NL) - Sildenafil exposure in neonates after extracorporeal membrane oxygenation for treatment of pulmonary hypertension W. Zhao (FR) - Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients Coffee Break Obesity Arne Astrup (DK) - Novel strategies for tackling the obesity epidemic GA Rongen (NL) - Rosiglitazone reduced ischemia-reperfusion–injury measured with annexin a5 scintigraphy. A randomized, double blind, placebo-controlled cross-over study in subjects with the metabolic syndrome H.J. Derijks (NL) - Influence of antidepressant use on glycemic control in patients with diabetes mellitus: an open-label comparative study drug approval process? g disease, Nephrology, Paediatric clinical pharmacology, Geriatric s, Rational prescribing Drugs for an Ageing Population Ulrich Klotz (DE) - Polypharmacy: is it inevitable? Stuart Ralston (UK) - Optimal protection for the ageing skeleton S. Mitchell (AU) - Estimation of lean body weight in frail and not frail older males S. Jackson (UK) - Improving and maintaining good quality prescribing Coffee Break Drugs for an Ageing Population G. Garhofer (AT) - Effect of dual endothelin receptor blockade on ocular blood flow in patients with glaucoma and healthy subjects R.A. Payne (UK) - Medication as a risk factor for falls - analysis using linked primary-secondary care data N. Wilson (AU) - Drug burden index as a predictor of falling in older people in residential aged care